Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients — Stella

Recruiting

Back to Systemic Lupus Erythematosus trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Ren Ji Hospital, Shanghai

Key details

Sponsor

RenJi Hospital

Enrollment target

~176 participants

Started

June 2024

Primary completion

June 2027

Age range

18 Years – 70 Years

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov